Pyridoxine for treatment of levetiracetam-induced behavioral adverse events: A randomized double-blind placebo-controlled trial.

Reza Alizadeh-Navaei, Hamed Cheraghmakani, Maryam Rezapour, Faezeh Asghari, Monireh Ghazaeian, Nasim Tabrizi

Journal: Epilepsy & behavior : E&B 2022;136():108938

PMID: 36228485

Full Text on Elsevier Science View on PubMed

Abstract

BACKGROUND

Levetiracetam is a broad-spectrum antiseizure medication with known behavioral side effects. The possible beneficial effect of pyridoxine on improvement of these psychiatric problems has been suggested in few previous studies. This clinical trial aimed to investigate the effect of pyridoxine on behavioral side effects of levetiracetam in adult patients with epilepsy.

METHODS

This study was a randomized double-blind placebo-controlled clinical trial on 53 adult patients with epilepsy with behavioral side effects after treatment by levetiracetam. Patients who met the study criteria were randomized to receive 40 mg/day pyridoxine or placebo. Their psychiatric state was surveyed by SCL-90-R questionnaire before and three weeks after initiation of treatment.

RESULTS

There were no statistically significant differences in the behavioral adverse effects between the pyridoxine-treated group and the placebo group.

CONCLUSION

Although this study showed no statistically significant beneficial effects of pyridoxine on the behavioral adverse effects of levetiracetam, placebo-controlled trials with a larger size and higher doses are needed to determine whether it is effective or not.

Address: Neurology Department, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.; Psychiatry and Behavioural Sciences Research Center, Addiction Institute, Department of Psychiatry, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.; Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.; Gastrointestinal Cancer Research Center, Non-communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran.; Pharmaceutical Research Center, Department of Clinical Pharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.; Neurology Department, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran. Electronic address: [email protected].

DOI: 10.1016/j.yebeh.2022.108938

Link outs

Free resources

Medical:

Miscellaneous:

https://assays.cancer.gov/CPTAC-1520

Research Materials:

https://antibodies.cancer.gov/detail/CPTC-KRT7-1

Subscription / membership required

Full Text Sources:

MeSH Terms: Adult, Humans, Levetiracetam, Piracetam, Pyridoxine, Anticonvulsants, Epilepsy, Double-Blind Method, Drug-Related Side Effects and Adverse Reactions, Treatment Outcome